Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
Sponsor: Vanderbilt University Medical Center
Summary
The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.
Official title: Evolving Biologic Administration: Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2025-10-16
Completion Date
2026-03-31
Last Updated
2026-02-17
Healthy Volunteers
No
Interventions
Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States